MP Healthcare Venture Management
Home About Us Portfolio News Contact
HomeAbout UsPortfolioNewsContact
MP Healthcare Venture Management
Forge Therapeutics Raises $15M Series A Financing to Develop First Novel Gram-Negative Antibiotic In Decades.
Brennan CaruthersApril 25, 2017
Facebook0 Twitter LinkedIn0 Reddit 0 Likes
Previous

Rigontec Starts First-In-Human, Phase I/II Trial of RIG-I Agonist RGT100 and Appoints Eugen Leo as Chief Medical Officer.

Brennan CaruthersMay 3, 2017
Next

miRagen Therapeutics Completes Merger with Signal Genetics and Concurrent $40.7 Million Equity Financing.

Brennan CaruthersFebruary 13, 2017

© 2010-2019 MP Healthcare Venture Management, Inc.
All Rights Reserved.

Privacy Policy | Terms of Use

About UsPortfolioNews Contact